Insula Centrum Badań Klinicznychsp. z o.o.
Other research and experimental development on natural sciences and engineering
KRS: NIP: REGON:
Overview
Status
Active
Registry date
2020-12-23
Share capital
5,000.00 PLN
Registered address
ul. Kłobucka 23C/109, 02-699 Warszawa, Poland
Financials
Revenue history (in k)
Filing timeliness
3 of 5 financial statements were filed late (the longest delay 401 days for 2022).
- 202511/06/2026
- 202411/03/2025
- 202330/08/2024
- 202219/08/2024
- 202118/07/2023
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Industry · Other research and experimental development on natural sciences and engineering256 / 1,565
Top 16%
Results vs industry
Revenue
This companyUSD 958.31kMedianUSD 73.26kAverageUSD 3.23m
Net profit
This companyUSD 74.07kMedianUSD 69.70AverageUSD 82.18k
Operating costs
This companyUSD 874.29kMedianUSD 75.78kAverageUSD 3.04m
Assets
This companyUSD 391.76kMedianUSD 119.88kAverageUSD 3.90m
Industry
Public procurement
1 tender recorded as contractor.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Nov 8, 2024 | Provision of diagnostic tests and specialist consultations. | –– | Wojewódzki Szpital Zespolony Im. Stanisława Rybickiego w Skierniewicach |
Authorized Representatives
Jakub Bartłomiej Stępień – President of the Management Board
Żanna Pastuszak Stępień – Attorney-in-fact
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner |
|---|
Natalia Anna Pastuszakage 40 |
Jakub Bartłomiej Stępieńage 39 |
Beneficial owners
| Person | Rights |
|---|---|
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 6, 2024 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $1,804$1,804 | Prezes Banku Gospodarstwa Krajowego |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Satagrosp. z o.o. | $1,365,254.65 | satagro.pl | ||
| Instytut Materiałów Budowlanych i Technologii Betonusp. z o.o. | $948,903.87 | imbitb.pl | ||
| DR Koziejsp. z o.o. + limited partnership | $770,078.78 | drkoziej.com | ||
| Florabosp. z o.o. | $765,897.40 | florabo.pl | ||
| 50bio.Comsp. z o.o. | $670,101.32 | 50bio.com | ||
| EkoparkS.A. | $585,284.10 | eko-park.org | ||
| Airway MedixS.A. | $512,838.82 | airway-medix.com | ||
| CTI Clinical Trial And Consulting Services Polandsp. z o.o. | $527,145.56 | ctifacts.com | ||
| Unia Producentów I Pracodawców Przemysłu Biogazowego I BiometanowegoEmployers' association | $480,518.70 | upebi.pl | ||
| Lemontechsp. z o.o. | $451,765.45 | lemontech.com.pl |
FAQ
The main business activity of Insula Centrum Badań Klinicznych focuses on other research and experimental development on natural sciences and engineering.
The company was registered in the Polish National Court Register (KRS) on December 23, 2020.
The headquarters is located at: ul. Kłobucka 23C, 02-699 Warszawa.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
In 2025, the company generated total revenue of $958,311, representing an increase of 17.1% compared to 2024.
Yes, in 2025 the company was profitable, achieving a net profit of $74,066, meaning the company decreased its profit by 21.6%.
The largest operating cost category falls under other operating costs. This category amounted to $605,407 in 2025, representing 69% of all operating expenses.
Last updated: 2026-07-16
